LY6H

Across TCGA pan-cancer cohorts, LY6H Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LY6H data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LY6H Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6H expression acts as an unfavorable survival marker.

SKCM are the cancer types where LY6H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.058	0.597	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LY6H–SKCM (DFS)

Open the SKCM breakdown →